NCT06128408View on ClinicalTrials.gov

The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset

Not yet recruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

October 12, 2024

Study Completion Date

October 13, 2024

Conditions

Treatment-resistant Schizophrenia

Interventions

DRUG

risperidone, olanzapine, aripiprazole

Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.

All Listed Sponsors

lead

Peking University

OTHER

NCT06128408 - The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset | Biotech Hunter | Biotech Hunter